Lyell Immunopharma: Pay

Lyell Immunopharma paid its 3 named executives $8.2M in total in FY2025 (Dec). CEO Lynn Seely, M.D. was paid $4.2M of that.

Pay$100 in the stock at the end of FY21 → $20
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Lynn Seely, M.D.President, Chief Executive Officer and Director
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years
Stephen HillChief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years
Gary Lee, Ph.D.Chief Scientific Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years

CEO pay against the pay peers

In FY2023 (Dec), the median CEO pay of the 11 peers with pay on file was $10.1M. The CEO of Lyell Immunopharma was paid $2.6M, 74% below the median.

  1. 1Relay Therapeutics
  2. 2Allogene Therapeutics
  3. 3CRISPR Therapeutics AG
  4. 4Intellia Therapeutics
  5. 5Revolution Medicines
  6. 6Arcus Biosciences
  7. 7Beam Therapeutics
  8. 8Iovance Biotherapeutics
  9. 9Fate Therapeutics
  10. 10Lyell Immunopharma
  11. 11Editas Medicine
  12. 12ImmunityBio
  13. 13Atara BiotherapeuticsNot disclosed
  14. 14Century TherapeuticsNot disclosed
  15. 15ErascaNot disclosed
  16. 16IGM BiosciencesNot disclosed
  17. 17Instil BioNot disclosed
  18. 18NGM BiopharmaceuticalsNot disclosed
  19. 19Prometheus BiosciencesNot disclosed
  20. 20Sana BiotechnologyNot disclosed
  21. 21Turning Point TherapeuticsNot disclosed
  22. 22Zentalis PharmaceuticalsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.